Обзидан (Propranolol) is relevant in conditions characterized by periods of heightened symptoms across multiple therapeutic domains. This medication is used in situations involving certain distressing symptoms related to the heart, including high blood pressure, angina (chest pain), and irregular heartbeats (arrhythmias).

The drug is commonly used across conditions presenting with episodic manifestations, specifically for the symptomatic management of migraine headaches and to address symptom clusters that may become intense or disruptive, such as essential tremor and the physical symptoms of anxiety. It may be part of the long-term management following a heart attack. This treatment supports patients during episodes of heightened discomfort and is applied in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with symptom fluctuations.

It is also considered relevant in conditions involving episodic or fluctuating manifestations, such as infantile hemangioma, and may be part of supportive symptom management for conditions involving functional stability of the circulatory system, such as portal hypertension.

---

Quick Fact: Symptom Management
Cardiovascular Use	Applied for managing symptoms linked to high blood pressure and irregular heart rate.
Neurological Use	Relevant for easing symptoms of essential tremor and recurrent migraine headaches.
Benefit Focus	Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Обзидан (Propranolol)?

The eligibility for using Обзидан is determined by official regulatory guidelines, primarily focusing on age and pre-existing health conditions. Eligibility criteria are standardized but may carry regional variations.

Contraindications (Must Not Use)

Обзидан is absolutely contraindicated in patients with specific severe conditions, including bronchial asthma, cardiogenic shock, decompensated (uncontrolled) heart failure, and sinus bradycardia or second/third-degree heart block (unless a pacemaker is present). Patients with severe hypotension, metabolic acidosis, or known hypersensitivity to the active ingredient must not use this medicine.

Age and Life-Stage Eligibility

Population	Eligibility Status (Regulatory Basis)
Adults	Eligible for general indications.
Older Adults	Eligible, but treatment requires caution, typically starting with the lowest dose.
Infants	Approved for a specific oral solution form to treat infantile hemangioma, restricted to infants aged 5 weeks to 5 months at initiation.
Pregnancy	Use is restricted (Category C), advised only when benefits clearly outweigh risks; neonates require monitoring after delivery.

Conditional Use Restrictions

Patients with hepatic impairment (liver disease) or renal impairment (kidney disease) are eligible but require caution and may need dosage adjustment. Caution is also necessary for patients with diabetes mellitus, as Обзидан may mask the signs of acute hypoglycemia.

Обзидан Interactions with other medicines and products

The interaction profile of Обзидан (Propranolol) is largely defined by its metabolism through multiple Cytochrome P-450 (CYP) enzymes, including CYP2D6, CYP1A2, and CYP2C19. Coadministration with drugs that inhibit these enzymes—such as the antiarrhythmic quinidine or the antidepressant fluoxetine—can increase Propranolol concentrations, potentially leading to increased clinical effects. Conversely, coadministration with enzyme inducers, such as rifampin or the practice of cigarette smoking, can increase the clearance of Propranolol, which may decrease its effectiveness.

Clinically significant interactions occur with several major medication classes:

• Cardiovascular Drugs: Caution is required with other agents that slow atrioventricular (AV) conduction or decrease heart rate, including calcium channel blockers (e.g., verapamil, diltiazem) and Digitalis glycosides. Concurrent use can increase the risk of bradycardia and cardiovascular collapse.
• Antiarrhythmics: Drugs like amiodarone and propafenone have effects that can be additive to those of Propranolol. The clearance of lidocaine is also reduced by coadministration, which may result in toxicity.
• Antacids: Certain aluminum-containing antacids may reduce Propranolol concentrations.

Regulatory documentation also indicates that Propranolol can inhibit the metabolism of other drugs, such as the antianxiety agent diazepam and the anticoagulant warfarin, necessitating careful monitoring of the prothrombin time for the latter.

Molecular Targeting: FPPS Inhibition

Обзидан is an inhibitor of farnesyl pyrophosphate synthase (FPPS), an enzyme critical for the function and survival of osteoclasts. The compound is internalized by the osteoclast via the amino-bisphosphonate moiety, disrupting the mevalonate pathway by binding to the active site of FPPS.

---

Intracellular Cascade and Osteoclast Apoptosis

This inhibition of FPPS prevents the prenylation of small GTPases required for the formation of the ruffled border and overall osteoclast activity. This mechanistic cascade leads to a dose-dependent reduction in osteoclast activity and apoptosis (programmed cell death).

---

Physiological Effect on Bone Remodeling

The resulting reduction in bone resorption contributes to a net positive change in bone turnover, thereby altering the balance of the bone remodeling unit. Furthermore, the compound is stored in the bone mineral matrix and is released locally during periods of increased bone turnover.

How to Use Обзидан

Обзидан (Propranolol) is primarily administered via the oral route, utilizing standard tablets, extended-release capsules, or an oral solution. The intravenous (IV) route is reserved for use by qualified personnel in acute, supervised clinical environments.

The official dosing regimens establish a clear sequence for administration. For standard tablets, treatment typically begins with a dose of 40 mg taken twice daily (b.i.d.). This dose is gradually adjusted over specified intervals, often every 3 to 7 days, toward a maintenance range, which commonly falls between 120 mg and 240 mg per day. The extended-release capsules are administered once daily (q.d.), typically starting at 80 mg.

Proper administration requires adherence to specific instructions regarding consumption. Oral doses must be taken consistently with respect to meals to maintain stable drug absorption. The extended-release capsules are mandated to be swallowed whole and must not be crushed or chewed, as this compromises the sustained-release mechanism.

The administration protocol includes mandatory population adjustments and a cessation procedure. For patients with hepatic impairment, a dose reduction is required due to the drug's metabolism. Furthermore, the official instructions require that the medicine must not be stopped abruptly; instead, a gradual dose reduction (tapering) must be implemented over a period of one to two weeks.

Recent Clinical Evidence

Research on Обзидан (Propranolol) focuses on its established applications in cardiovascular conditions and emerging uses in other fields. The studies described here track participant responses, not therapeutic recommendations.

---

Cardiovascular and Neurological Research

Area of Investigation	Study Type & Focus	Observation in Research
Post-Myocardial Infarction	Randomized, controlled trials in high-risk survivors.	Studies documented reductions in total mortality and sudden cardiac death when the drug was administered in the post-infarction period.
Essential Tremor	Comparative studies (e.g., against amantadine) in people with Parkinson's disease.	Studies documented changes in tremor severity scores and monitored for side effects such as tiredness and dizziness.

---

Extended and Investigational Use

Research has explored the drug's profile in non-cardiac conditions:

• Infantile Hemangioma (IH): Meta-analyses and cohort studies have investigated the use of the drug in infants with hemangiomas. Studies documented a reduction in hemangioma depth and size compared to initial measurements.
• Anxiety and Stress: Research has tracked the drug's effects on physical symptoms of anxiety, such as tachycardia, in the context of situational anxiety and performance stress. Other studies have monitored effects related to memory processing following trauma.
• Tolerability: Research investigated participant response to the drug during extended periods of use. Studies assessed changes in physiological markers, including heart rate, blood pressure, and liver enzyme levels, noting that most changes remained within normal ranges in monitored cohorts.

Common questions about Обзидан (FAQ)

Q: Is the brand name Обзидан different from generic Propranolol?

The active ingredient in the brand-name Обзидан is propranolol. Official regulatory documents indicate that the brand drug, particularly the extended-release capsule, is considered therapeutically equivalent to the generic propranolol formulation. Therapeutic equivalence means the two versions are expected to have the same clinical effects for indications like blood pressure management.

Q: How long does it usually take for Обзидан to have its full effect for high blood pressure?

According to official prescribing information, the full effect for high blood pressure is not achieved immediately. The process of dose adjustment occurs over intervals, often 3 to 7 days, to find a stable level. The full therapeutic benefit may then take several weeks to stabilize after a consistent regimen is reached.

Q: Does Обзидан start working immediately for fast heart rate or tremor symptoms?

The time it takes for the medicine to reach its highest concentration in the blood depends on the formulation used. For the standard tablet, peak blood levels occur about 1 to 4 hours after dosing. The extended-release capsule is designed to release the drug more slowly, with peak levels occurring around 6 hours after dosing.

Q: Is weight gain a possible effect described in official information for Обзидан?

Studies and official information indicate that weight gain has been reported as an adverse reaction. It is typically classified as an uncommon or less frequent effect associated with this class of medication in surveillance reports.

Q: Can Обзидан affect sexual health?

According to official product information, certain effects related to sexual health have been reported. These include impotence (erectile dysfunction) and a decrease in libido (sex drive). These are classified as potential adverse reactions associated with the use of this medicine.

Q: Are there common over-the-counter pain relievers that interact with Обзидан?

Official regulatory documents mention that Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may interact with Обзидан. Taking OTC pain relievers like ibuprofen concurrently may lessen the blood pressure-lowering effects of the medication.

Q: Is it true that Обзидан can interact with some asthma medicines?

Regulatory documents indicate that the medicine is generally contraindicated in patients with asthma. Official information states that the drug can block the airway-opening effects (bronchodilation) provided by some asthma medications.

Q: Can Обзидан mask the symptoms of a heart attack?

Abruptly stopping the medication in people with pre-existing heart disease has been associated with a worsening of chest pain and the potential for myocardial infarction (heart attack). The medicine can also mask the typical warning signs of other underlying conditions, such as low blood sugar (hypoglycemia).

Q: What are the official sources describing the potential for hair loss related to Обзидан?

Alopecia, which is the medical term for hair loss, is listed as a potential adverse reaction in official safety documentation. This side effect is usually classified as rare or reported based on post-marketing experience.

Q: What is the concern about using Обзидан with certain antidepressants?

Certain classes of antidepressants may interact with Обзидан by affecting how the body processes the drug. These interactions, specifically involving the CYP2D6 enzyme, can increase the amount of propranolol in the blood, potentially increasing the risk of adverse effects.

Q: How long does one dose of Обзидан typically last?

The duration of the dose depends on the formulation used. The extended-release capsules are formulated to release the medicine over a full 24-hour period. The medicine has an apparent plasma half-life of about 10 hours.

Q: Is Обзидан a medicine that is usually intended for long-term use?

Official regulatory documents indicate that the medicine is used for the management of chronic conditions. These conditions, such as hypertension (high blood pressure) and migraine prevention, are typically managed with long-term therapeutic strategies.

Q: Are there any foods or supplements that official sources suggest avoiding?

Official product information notes that the absorption of the medicine is increased when taken with food, requiring that administration be consistent in relation to meals. Additionally, certain aluminum-containing antacids may reduce the amount of the drug absorbed.

Q: Can older adults safely use Обзидан?

Older adults are eligible to use the medicine, but official guidelines recommend careful consideration. Due to potential changes in how the body processes the drug, special attention is generally paid to the initial dosage.

Q: Is Обзидан considered safe for people who drive or operate machinery?

Official patient information indicates that, due to the potential for common adverse reactions like dizziness and fatigue, attention should be paid to how the medicine affects concentration and physical ability before engaging in activities like driving or operating machinery.

Q: Is there research on Обзидан for pediatric patients?

Official regulatory documents confirm a specific approved use in infants. The oral solution form is indicated for the treatment of proliferating infantile hemangioma (IH) in infants aged 5 weeks to 5 months at the start of treatment.

Q: What kind of monitoring may be required while using Обзидан?

Certain patient populations may require monitoring as outlined in regulatory documentation. For example, patients taking blood thinners like warfarin may require monitoring of their prothrombin time. Regulatory information notes that patients with diabetes should be closely observed for signs of low blood sugar (hypoglycemia).

Q: Is it normal to have a lower resting heart rate while taking Обзидан?

A decrease in heart rate is an expected result of the medicine's mechanism of action, as it works to reduce the overall workload on the heart. However, regulatory documents also list a heart rate that is too slow, known as bradycardia, as a common adverse reaction.

Q: Is it possible to overdose on Обзидан?

Yes, overdosage is possible and can lead to severe adverse effects as described in the official product information. These serious potential effects include a very slow heart rate (profouind bradycardia), extremely low blood pressure (hypotension), and cardiogenic shock.

Q: Does the time of day matter when taking the medicine?

Official administration instructions indicate that the time of day can matter depending on the formulation used. The extended-release capsules, which are taken once daily, are commonly directed to be taken at bedtime to help maintain consistent blood levels.

The storage and disposal of Обзидан (Propranolol) must adhere strictly to official regulatory guidelines to maintain product quality and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep the medicine away from light, excess heat, and moisture (do not store in a bathroom).
Container	Keep in the original container and ensure it is tightly closed; do not freeze the medication.
Stability Note	The Propranolol oral solution must be discarded 2 months after first opening the bottle.

Disposal and Safety

The product must be stored out of the sight and reach of children. Any unused or expired medicine should be disposed of in accordance with local requirements. If no take-back program is available, the product can generally be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed container before throwing it in the household trash, as per federal guidelines.